CCM
ITOS

Cinctive Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Cinctive Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23,200
Closed -$747K – 570
2022
Q1 		$747K Buy
23,200
+2,000
+9% +$72.7K 0.03% 416
2021
Q4 		$987K Buy
+21,200
New +$706K 0.04% 408

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cinctive Capital Management's ITOS Position: Q2 2022 in Review

Cinctive Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2022, closing a stake of 23,200 shares — an estimated $747K sold.

Cinctive Capital Management first reported a position in ITOS in Q4 2021 and held it in 2 quarters. The position peaked at $987K in Q4 2021. 152 funds tracked by Wall St. Rank hold ITOS as of Q2 2022.

  • Cinctive Capital Management reported no remaining iTeos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cinctive Capital Management sold 23,200 iTeos Therapeutics shares in Q2 2022, an estimated $747K.
  • Cinctive Capital Management first reported a position in iTeos Therapeutics in Q4 2021 and held it in 2 quarters.
  • Cinctive Capital Management's iTeos Therapeutics position peaked at $987K in Q4 2021.
  • 152 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2022.

Based on Cinctive Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.